



# Clinical, Epidemiological Features and Outcomes of Blastomycosis in A Tertiary Hospital in Kentucky

Evelyn Villacorta Cari MD<sup>1</sup>, Julie Ribes MD, PhD<sup>2</sup>, Nicole Leedy MD<sup>1</sup>, Jaime Soria MD<sup>1</sup>, Thein Myint MBBS<sup>1</sup>

<sup>1</sup>Infectious Diseases Division, <sup>2</sup>Pathology and Laboratory Medicine. University of Kentucky College of Medicine, Lexington, KY, USA

Abstract ID: 908980

## INTRODUCTION

- Blastomycosis, caused by *Blastomyces dermatitidis*, is endemic in areas of the United States and Canada surrounding the Ohio and Mississippi River valleys and the Great Lakes.<sup>1</sup> It can present with subclinical infection to acute respiratory distress syndrome.<sup>2,3</sup>
- The risk factors associated with severe manifestation of blastomycosis are not well defined.

## METHODOLOGY

- A retrospective study of patients diagnosed or treated for blastomycosis at the University of Kentucky from January 2004-March 2019 were included.
- Severe cases were defined as patients that required ICU care.
- Logistic regression was used to identify variables associated with severe infections

Table 1: Characteristics of Patients with Blastomycosis

| Characteristics                         | Total<br>n=82    | Immunosuppressed<br>n=26 | Immunocompetent<br>n=56 | p-value      |
|---|------------------|--------------------------|-------------------------|--------------|
| Age, y [range]                          | 48 (16 - 89)     | 61 (37-85)               | 40 (16-89)              | <b>0.001</b> |
| Gender, male                            | 66 (80.5%)       | 23 (88.4%)               | 43 (76.7%)              | 0.250        |
| Race, white                             | 71 (92.2%)       | 22 (95.6%)               | 49 (90.7%)              | 1.000        |
| Tobacco use                             | 52 (68.3%)       | 18 (69.1%)               | 34 (68.0%)              | 0.308        |
| DM                                      | 24 (29.2%)       | 9 (34.6%)                | 15 (26.7%)              | 0.603        |
| COPD                                    | 21 (25.6%)       | 8 (30.7%)                | 13 (23.2%)              | 0.588        |
| BMI>30                                  | 25/77 (32.4%)    | 8 (32.0%)                | 17 (32.6%)              | 1.000        |
| CNS symptoms                            | 4 (4.8%)         | 3 (11.5%)                | 1 (1.7%)                | 0.092        |
| Inpatient admission                     | 61 (74.3%)       | 23 (88.4%)               | 38 (67.8%)              | 0.059        |
| ICU admission                           | 19 (31.1%)       | 10 (43.4%)               | 9 (23.6%)               | 0.154        |
| Mortality                               | 11 (13.4%)       | 6 (23.0%)                | 5 (8.3%)                | 0.094        |
| WBC, [range],<br>(x10 <sup>3</sup> /μl) | 11.2 (0.9-40.7)  | 11.6 (0.9-40.7)          | 11.2 (4.8-35.8)         | 0.845        |
| AST,[range],(U/l)                       | 20 (6-227)       | 17 (6-69)                | 24 (7-227)              | <b>0.028</b> |
| ALT,[range], (U/l)                      | 21 (5-432)       | 17 (8-68)                | 22 (5-432)              | 0.074        |
| Creatinine,[range],<br>(mg/dL)          | 0.93 (0.26-6.98) | 0.99 (0.44-2.35)         | 0.92 (0.26-6.98)        | 0.638        |

Figure 1: Type of presentation




Table 2: Distribution of diagnostic tests results

|                                 | n(%)          |
|---------------------------------|---------------|
| Positive KOH stain              | 31/60 (51.6%) |
| Positive culture                | 59/69 (85.5%) |
| Bronchoalveolar lavage          | 20 (29.4%)    |
| Sputum                          | 13 (19.1%)    |
| Lung Tissue                     | 11 (16.1%)    |
| Skin                            | 5 (7.3%)      |
| Bone                            | 4 (5.8%)      |
| Brain                           | 2 (2.9%)      |
| Other                           | 6 (8.8%)      |
| Positive Histopathology for BBB | 48/67 (71.6%) |
| Bronchoalveolar lavage          | 17 (25.3%)    |
| Lung Tissue                     | 12 (17.9%)    |
| Skin                            | 9 (13.4%)     |
| Bone                            | 2 (2.9%)      |
| Other                           | 12 (17.9%)    |
| Histoplasma antigen, serum      | 9/14 (64.2%)  |
| Histoplasma antigen, urine      | 33/44 (70.2%) |
| Blastomyces antigen             | 16/24 (66.6%) |
| Blastomyces antibody EIA        | 19/55 (34.5%) |
| Blastomyces antibody ID         | 6/55 (11.1%)  |
| Histoplasmas mycelial CF        | 1/55 (1.8%)   |
| Histoplasmas yeast CF           | 7/55 (12.7%)  |
| Histoplasma antibody ID         | 2/55 (3.6%)   |

Table 3: Univariate and Multivariate analysis for the associated risk factors for severe infection

|   | Univariate analysis |            |       | Multivariate analysis |             |              |
|---|---------------------|------------|-------|-----------------------|-------------|--------------|
|   | IRR                 | [95% CI]   | p     | IRR                   | [95% CI]    | p            |
| Age older than 50y                          | 4.02                | 1.60-10.09 | 0.003 | 3.55                  | 1.42 – 8.83 | <b>0.006</b> |
| Male, sex                                   | 0.96                | 0.37-2.52  | 0.950 | 1.96                  | 0.84 – 4.55 | 0.117        |
| Diabetes                                    | 2.95                | 1.40-6.22  | 0.004 | 2.52                  | 1.16 – 5.50 | <b>0.019</b> |
| Obesity                                     | 2.60                | 1.16-5.80  | 0.020 | 3.11                  | 1.42 – 8.83 | <b>0.005</b> |
| Hb <10g/dL                                  | 2.27                | 1.06-4.84  | 0.033 | 3.01                  | 1.55 – 5.85 | <b>0.001</b> |
| WBC <4.0 or >12.0<br>(x10 <sup>3</sup> /μl) | 1.04                | 1.01-1.07  | 0.001 | 1.03                  | 1.00 – 1.07 | <b>0.030</b> |

## RESULTS

- A total of 82 patients were included. Table 1
- Immunosuppressed cases: Malignancies (19 cases), autoimmune diseases (5 cases), chronic steroid use (3 cases), and transplant (2 cases). No HIV case was found. (figure 1), immunosuppression was not found to have any impact in mortality ( $p=0.094$ ).
- Urine *Histoplasma* or *Blastomyces* antigen was positive in 41/58 (70.6%), and Serum *Histoplasma* or *Blastomyces* antigen was positive in 22/34 (64.7%) (Table 2).
- Initial antifungal treatment was amphotericin B liposomal in 38/80 (47.5%).
- A multivariable analysis was performed to find predictors of severe blastomycosis infection (Table 3).

## CONCLUSION

- Pulmonary Blastomycosis is the most common presentation, independent factors associated to severe disease were older age, obesity, diabetes, and anemia at admission.
- Culture and histopathology are more sensitive than antigen assay. Serology is the least sensitive assay.

### References

- Castillo, C. G., et al. (2016). *Infect Dis Clin North Am* 30(1): 247-264.
- McBride, J. A., et al. (2017). *Clin Chest Med* 38(3): 435-449.
- Lohrenz, S., et al. (2018). " *Med Mycol* 56(7): 787-795.